PEOPLE - ReGen Biologics makes appointment:
This article was originally published in Clinica
ReGen Biologics has appointed Dr Shu-Tung Li to the new position of senior vice-president of research. ReGen is a US tissue engineering company specialising in the repair and preservation of the knee.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.